Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study.
Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study.
复制标题
DOI：
10.1007/s00520-021-06619-6
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Gok Metin Z
中科院分区：
文献类型：
--
作者：
Gokce Ceylan G;Gok Metin Z
广泛应用于临床治疗的紫杉醇疗法给患有乳腺癌（BC）的女性带来了许多负面的身体和心理后果。这项纵向研究首先旨在调查接受紫杉醇治疗的 BC 患者的症状状态、身体知觉变化以及焦虑和抑郁的风险。这项描述性和前瞻性研究是对 84 名接受紫杉醇治疗方案的 BC 患者进行的。在五个时间点应用“化疗症状评估量表（C-SAS）”、“身体感知量表（BPS）”和“医院焦虑抑郁量表（HADS）”（T1，第一次紫杉醇输注前；T2，第一个周期结束时；T3，第四个周期结束时；T4，第八个周期结束时；T5，第十二个周期结束时）。使用描述性统计、Cochrane Q 和线性混合模型回归分析来分析数据。与初始评估（T1）相比，后续评估点（T2、T3、T4 和 T5）中手足针刺和麻木、疼痛以及皮肤或指甲变化的频率显着增加（p<0.05）。与T1相比，T2、T4和T5的BPS平均分显着下降（F = 8.152，p < 0.001）。 HADS量表焦虑分量表的平均分在T3、T4和T5时较T1下降（F = 6.865，p < 0.001），而抑郁分量表的平均分在T5时较T1显着升高（F = 3.708，p = 0.006）。肿瘤科护士应对计划接受紫杉醇治疗的患者进行全面评估，并在特定周内为患者提供咨询。通过在护士的监督下反复询问来更好地管理因紫杉醇治疗而增加的症状，也将防止身体知觉恶化。此外，由于接受紫杉醇治疗的患者患抑郁症的风险随着时间的推移而增加，护士应定期筛查抑郁症的风险，并及时咨询患者以获得适当的支持。
Paclitaxel regimen which is widely used in clinical treatment causes many negative physical and psychological consequences on women with breast cancer (BC). This longitudinal study firstly aimed to investigate symptom status, body perception changes, and the risk of anxiety and depression in BC patients receiving during paclitaxel regimen. This descriptive and prospective study was conducted with 84 BC patients receiving paclitaxel regimen. “Chemotherapy Symptom Assessment Scale (C-SAS),” “Body Perception Scale (BPS),” and “Hospital Anxiety and Depression Scale (HADS)” were applied at five time points (T1, before the first Paclitaxel infusion; T2, at the end of first cycle; T3, at the end of fourth cycle; T4, at the end of eighth cycle; T5, at the end of twelfth cycle). Data was analyzed using descriptive statistics, Cochrane Q, and linear mix model regression analysis. The frequency of needling and numbness in hands and feet, pain, and skin or nail changes significantly increased in the subsequent assessment points (T2, T3, T4, and T5) compared to the initial assessment (T1) (p < 0.05). The mean scores of BPS significantly decreased at T2, T4, and T5 compared to T1 (F = 8.152, p < 0.001). The mean scores of the anxiety subscale of the HADS scale decreased at the T3, T4, and T5 compared to T1 (F = 6.865, p < 0.001), and the mean scores of the depression subscale significantly increased at the T5 compared to T1 (F = 3.708, p = 0.006). The oncology nurse should comprehensively evaluate the patients who scheduled to receive paclitaxel treatment, and provide counseling to the patients during these specific weeks. Better management of the symptoms that increase with the paclitaxel regimen with repeated interviews under the supervision of the nurse will also prevent the deterioration of body perception. In addition, since the risk of depression increases over time in patients receiving paclitaxel, nurses should periodically screen the risk of depression, and timely consult the patients for the appropriate support.
登录
查看更多内容
DOI：
10.1055/s-0037-1601453
发表时间：
2017-04-01
期刊：
Revista Brasileira de Ginecologia e Obstetrícia
影响因子：
--
作者：
Prates, Ana Carolina Lagos;Freitas-Junior, Ruffo;Barros, Norami de Moura
通讯作者：
Barros, Norami de Moura
影响因子：
2.6
作者：
Oh, Pok-Ja;Cho, Jung-Ran
通讯作者：
Cho, Jung-Ran
影响因子：
1.6
作者：
Izci, Filiz;Ozdem, Gozdem;Ozmen, Vahit
通讯作者：
Ozmen, Vahit
影响因子：
3.6
作者：
Choi, Eun Kyung;Kim, Im-Ryung;Cho, Juhee
通讯作者：
Cho, Juhee
影响因子：
1.8
作者：
Chan YN;Jheng YW;Wang YJ
通讯作者：
Wang YJ